Chong Kun Dang Pharmaceutical (185750) — Cash Flow Quality Index
Chong Kun Dang Pharmaceutical (185750) has a Cash Flow Quality Index of 0.96x as of March 2026. Operating cash flow of ₩12.32 Billion is below net income of ₩12.82 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore debt repayment capacity of Chong Kun Dang Pharmaceutical to assess how comfortably operating cash covers total debt obligations.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Chong Kun Dang Pharmaceutical Cash Flow Quality Index (2016–2025)
Historical Cash Flow Quality Index for Chong Kun Dang Pharmaceutical across 10 annual periods. Values consistently above 1.0x indicate high-quality earnings. For the full cash flow conversion analysis, see cash flow conversion of Chong Kun Dang Pharmaceutical.
Annual Cash Flow Quality Index for Chong Kun Dang Pharmaceutical (2016–2025)
Year-by-year earnings quality comparison for Chong Kun Dang Pharmaceutical.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2025 | 0.87x | ₩67.36 Billion | ₩77.51 Billion | ▲ +45.6% |
| 2024 | 0.60x | ₩64.29 Billion | ₩107.70 Billion | ▼ -60.8% |
| 2023 | 1.52x | ₩318.16 Billion | ₩208.86 Billion | ▲ +79.9% |
| 2022 | 0.85x | ₩67.73 Billion | ₩79.98 Billion | ▲ +158.7% |
| 2021 | 0.33x | ₩12.90 Billion | ₩39.42 Billion | ▼ -71.2% |
| 2020 | 1.14x | ₩104.32 Billion | ₩91.63 Billion | ▼ -20.6% |
| 2019 | 1.43x | ₩77.29 Billion | ₩53.88 Billion | ▲ +42.7% |
| 2018 | 1.01x | ₩42.63 Billion | ₩42.40 Billion | ▼ -33.8% |
| 2017 | 1.52x | ₩81.67 Billion | ₩53.81 Billion | ▲ +7.6% |
| 2016 | 1.41x | ₩57.79 Billion | ₩40.95 Billion | — |